drugset / Trial / NCT01518309
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
Timeline
- Start
- 2004-11-17
- Primary completion
- 2013-05-02
- Completion
- 2013-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | 20 mg | Oral |
| Subject | Pimavanserin | Small molecule | 40 mg | Oral |
| Subject | Pimavanserin | Small molecule | 60 mg | Oral |